Helixgate https://validator.w3.org/feed/docs/rss2.html FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize Home Virtual biotech company puts thousands of AI scientist agents to work on drug discovery New bioinformatics tools help identify pathogenic variants in the genome Discovery of CRISPR’s long lost ancestor may expand gene-editing toolkit Eli Lilly dishes out fresh produce to cultivate Alzheimer’s awareness Clinical trials reach a new automation inflection point Europe’s CHMP endorses slew of new medicines, including new offerings from Novo and AZ Fierce Pharma Asia—China deals safe from COINS?; Key WCLC data; Legend’s new CEO FDA approves Ultragenyx’s gene therapy Fayuvi for rare neurodegenerative disorder Bayer’s Kerendia secures FDA nod as first drug in 30 years for Type 1 diabetes-associated kidney disease Roche’s Lunsumio delivers positive confirmatory trial readout in follicular lymphoma Eli Lilly escalates oral SERD battle with FDA approval for Inluriyo, Verzenio combo Roche, Dualitas team up to find bispecific drugs for immune diseases North Immunology joins biotech reverse merger boom with Aethlon deal Novo partners with Orbis, deepening investment in oral peptide drugs Lisata deal propels Marea’s drug pipeline to Wall Street Electra amasses $350M in biotech’s latest big IPO Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug This week in charts: GSK’s China deals, the $300M IPO club and selling the news Xenon shares fall following depression trial pause A national security priority: BIO pushes PAHPA reauthorization in 2026 With Tepezza challenge in late-stage study, Sling draws $123M series C: Venture Report Scale as strategy: Blackstone’s Galakatos on funding the hardest mile SK pens $315M pact with fellow South Korean company for Parkinson’s prospect Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’ Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcohol After one failed acquisition attempt, Lisata finds lifeline in Marea merger Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive North Immunology goes public via reverse merger as eczema drug heads toward clinic Xenon pauses phase 3 depression trials after psychosis events BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data Inflammation biotech Electra charges up with $350M from upsized IPO Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential STAT+: A biotech hedge fund births a new immunology company  STAT+: A Sellas immunotherapy study, long delayed, will end in failure STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease Bayer’s Kerendia (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes FDA Approves Fayuvi (rebisufligene etisparvovec-hopf) Gene Therapy for the Treatment for Sanfilippo Syndrome Type A (MPS IIIA) Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy Cellares and GenomeFrontier to assess automated GF-CART01 production Boehringer launches hub for patient experience data Roche bets up to $1B to advance next-gen bispecifics with Dualitas Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial After Novartis’ devastating M&A losses, long live the executive willing to try Webinar: Manufacturing in Turbulent Times Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs C3TI Compass (Knowledge Repository) Reporting Prescription Drug Sample Losses, Known Thefts, and Possible Diversion in the Aftermath of a Natural Disaster Novo’s Denecimig Demonstrates Tolerability After Switch from Emicizumab in FRONTIER5 Study of People with Haemophilia A as Published in the Journal of Thrombosis and Haemostasis